# US 2014/0271851 A1 · Antiemetic extended release solid dosage forms

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2014/0271851 A1
- Document ID: US20140271851A1
- Status: Published application
- Kind: A1
- Application number: 14/212,954
- Filed: 2014-03-14
- Published: 2014-09-18
- Earliest claimed: 2013-03-14
- Assignees: RedHill Biopharma Ltd.
- Applicants: RedHill Biopharma Ltd.
- Inventors: Reza Fathi; Gilead Raday; Patrick Gosselin; Guy Goldberg
- Web page: https://patentgrep.com/patent/US20140271851A1

## CPC

- A61K 9/286: {Polysaccharides, e.g. gums; Cyclodextrin}
- A61K 9/209: {containing drug in at least two layers or in the core and in at least one outer layer}
- A61K 9/2886: {having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer (of the type active core-drug layer-inactive layer A61K9/209)}
- A61K 31/4178: not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
- A61P 1/08: for nausea, cinetosis or vertigo; Antiemetics
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K 9/2013: {Organic compounds, e.g. phospholipids, fats}
- A61K 9/2054: {Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose}
- A61K 9/2846: {Poly(meth)acrylates}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A pharmaceutical formulation includes (1) a first dosage component comprising: a core comprising a non-ionic polymer matrix, a first amount of ondansetron or an equivalent amount of an ondansetron salt thereof dispersed within the matrix, and an electrolyte dispersed within the matrix; a first seal coat surrounding the core, the first seal coat comprising a non-ionic polymer matrix; and an immediate release drug layer surrounding the first seal coat, wherein the immediate release drug layer comprises a non-ionic polymer and a second amount of ondansetron or an equivalent amount of an ondansetron salt thereof dispersed therein; and (2) a second dosage component comprising: a core comprising a third amount of ondansetron or an equivalent amount of an ondansetron salt thereof, at least one filler, and a lubricant; and a coating surrounding the core, the coating comprising water and a mixture of methacrylic acid-alkyl acrylate copolymers with alkaline groups.

## Claims

### Claim 1

A pharmaceutical formulation comprising:
(1) a first dosage component comprising:
a core comprising a non-ionic polymer matrix providing sustained release, a first amount of ondansetron or an equivalent amount of an ondansetron salt thereof dispersed within the matrix, and an electrolyte dispersed within the matrix;
a first seal coat surrounding the core, the first seal coat comprising a non-ionic polymer matrix; and
an immediate release drug layer surrounding the first seal coat, wherein the immediate release drug layer comprises a non-ionic polymer and a second amount of ondansetron or an equivalent amount of an ondansetron salt thereof dispersed therein; and
(2) a second dosage component comprising:
a core comprising a third amount of ondansetron or an equivalent amount of an ondansetron salt thereof, at least one filler, and a lubricant; and
a coating surrounding the core, the coating comprising water and a mixture of methacrylic acid-alkyl acrylate copolymers with alkaline groups.

### Claim 2 (depends on 1)

The pharmaceutical formulation of claim 1 wherein the core of the first dosage component is a compressed core.

### Claim 3 (depends on 1)

The pharmaceutical formulation of claim 1 wherein the core of the second dosage component is a compressed core.

### Claim 4 (depends on 1)

The pharmaceutical formulation of claim 1 wherein the coating of the second dosage component includes a mixture of Eudragit® RS to Eudragit® RL,

### Claim 5 (depends on 4)

The pharmaceutical formulation of claim 4 wherein a Eudragit® RS/Eudragit® RL ratio is 8 to 2.

### Claim 6 (depends on 1)

The pharmaceutical formulation of claim 1 wherein the coating of the second dosage component further includes talc.

### Claim 7 (depends on 1)

The pharmaceutical formulation of claim 1 wherein the coating of the second dosage component comprises:
from about 30% (w/w) to about 55% (w/w) of purified water;
from about 25% (w/w) to about 45% (w/w) of Eudragit® RS 30D;
from about 3.0% (w/w) to about 25% (w/w) of Eudragit® RL 30D; and
from about 1.0% (w/w) to about 6.0% (w/w) of talc.

### Claim 8 (depends on 1)

The pharmaceutical formulation of claim 1 wherein the first component and the second component are compressed together.

### Claim 9 (depends on 1)

The pharmaceutical formulation of claim 1 wherein the first component and the second component are two separate units.

### Claim 10 (depends on 1)

The pharmaceutical formulation of claim 1 wherein the first amount of ondansetron is about 20 mg of active free base.

### Claim 11 (depends on 1)

The pharmaceutical formulation of claim 1 wherein the first amount of ondansetron is about 28 mg of active free base.

### Claim 12 (depends on 1)

The pharmaceutical formulation of claim 1 wherein the second amount of ondansetron is about 8 mg of active free base.

### Claim 13 (depends on 1)

The pharmaceutical formulation of claim 1 wherein the third amount of ondansetron is about 8 mg of active free base.

### Claim 14 (depends on 1)

A packaged pharmaceutical preparation comprising a plurality of the pharmaceutical formulations of claim 1 in a sealed container and instructions for administering the pharmaceutical formulations orally to effect prevention of nausea and vomiting.

### Claim 15 (depends on 1)

A packaged pharmaceutical preparation comprising a plurality of the pharmaceutical formulations of claim 1 each in a discrete sealed housing, and instructions for administering the pharmaceutical formulations orally to effect prevention of nausea and vomiting.

### Claim 16 (depends on 1)

A method for preventing nausea and vomiting comprising the step of administering the pharmaceutical formulation of claim 1 to a patient.

### Claim 17 (depends on 1)

The pharmaceutical formulation of claim 1 wherein the single oral dosage form is sufficiently designed to release all of the ondansetron over a minimum period of 36 hours.

### Claim 18 (depends on 1)

The pharmaceutical formulation of claim 1 wherein the single oral dosage form is sufficiently designed to release all of the ondansetron over a minimum period of 40 hours.

### Claim 19 (depends on 1)

The pharmaceutical formulation of claim 1 wherein the single oral dosage form is sufficiently designed to release all of the ondansetron over a minimum period of 44 hours.

### Claim 20 (depends on 1)

The pharmaceutical formulation of claim 1 wherein the single oral dosage form is sufficiently designed to release all of the ondansetron over a minimum period of 48 hours.

### Claim 21 (depends on 1)

The pharmaceutical formulation of claim 1 sufficiently designed to meet the two stage test dissolution profile in a basket apparatus:
(a) release of not more than 25% of the total amount of ondansetron in 2 hours in an acid stage comprising 900 ml 0.1N HCl at 50 rpm; and
(b) release of not less than 40% of the total amount of ondansetron in 30 hours in 900 ml phosphate buffer pH 6.8 at 50 rpm following the acid stage.
